It’s been a subdued—albeit sunny—start to healthcare’s biggest conference in San Francisco. | It’s been a subdued—albeit ...

Gary Gibbons, M.D., is retiring as National Heart, Lung and Blood Institute (NHLBI) director, adding to the e | Gary Gibbons, ...

Lyra Therapeutics is abandoning work on its rhinosinusitis treatment and laying off its remaining employees.

The life sciences world is once again converging in San Francisco as the J.P. Morgan Healthcare Conference kicks off for 2026 ...

Thermo Fisher Scientific is starting 2026's J.P. Morgan Healthcare Conference with a bang, announcing two new deals with an ...

Eli Lilly and Nvidia, two primary drivers of the recent stock market rally, are deepening their alliance to connect silicon ...

A phase 3 rheumatoid arthritis trial of Lynk Pharmaceuticals’ JAK1 inhibitor in China has hit its primary endpoint, boosting ...

Novartis’ continuing search for new ways to take drugs into the brain has resulted in a $1.7 billion deal with SciNeuro ...

Boston Scientific is buying up privately owned medtech Valencia Technologies for its implantable device aimed at helping ...

After a six-month battle, Edwards Lifesciences has been forced to walk away from its nearly $1 billion takeover attempt of ...

AbbVie has made no secret of the fact that it’s taken an interest in the hotly contested PD-1xVEGF bispecific space. | AbbVie has made no secret of the fact that it's taken an interest in the hotly ...

Bayer, looking to bolster its position in both imaging and cardiac medicine, struck a deal to snap up two experimental imaging agents and thereby enter the diagnostic tracers development space. | ...